Neural Regeneration Research ›› 2026, Vol. 21 ›› Issue (6): 2363-2364.doi: 10.4103/NRR.NRR-D-25-00505

Previous Articles     Next Articles

Annexin A1 in Alzheimer’s disease: a new therapeutic strategy focusing on neuroinflammation

Luiz Philipe de Souza Ferreira*, Cláudia A. Valente, Cristiane D. Gil*   

  1. Structural and Functional Biology Graduate Program, Escola Paulista de Medicina, Universidade Federal de São Paulo (UNIFESP), 
    São Paulo, SP, Brazil (Ferreira LPS, Gil CD)
    Instituto de Farmacologia e Neurociências, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal (Ferreira LPS, Valente CA)
  • Online:2026-06-15 Published:2026-04-16
  • Contact: Luiz Philipe de Souza Ferreira, PhD candidate, luiz.philipe@unifesp.br; Cristiane D. Gil, PhD, cristiane.gil@unifesp.br.
  • Supported by:
    The work in our laboratory was funded by the São Paulo Research Foundation (FAPESP; grant No. 2022/02327-6). LPSF is supported by the FAPESP scholarships (2021/00270-4 and 2024/054917). CDG is a research fellow of the Brazilian National Council for Scientific and Technological Development (CNPq).

PDF

5

Abstract: Neurodegenerative diseases affect millions of people worldwide, with Alzheimer’s disease (AD) being the leading cause of dementia. It is estimated that more than 50 million people live with this condition, which is expected to triple by 2050, driven mainly by the aging of the global population (GBD 2019 Dementia Forecasting Collaborators, 2022). The pathogenesis of AD is characterized by a complex interplay of genetic, molecular, and cellular mechanisms, particularly involving amyloid-beta (Aβ) and Tau proteins. These processes trigger the reactivity of glial cells, which in turn contributes to the degeneration of hippocampal neurons and a significant reduction in synapse density (Van Zeller et al., 2021).